Evidence map›Paper›PMID 42832112›Full record

ArticleJournal of neurology2026

Clinical features and prognosis of EGPA-associated peripheral neuropathy: a multicentre REVEAL cohort study.

Yuichi Masuda, Shogo Matsuda, Ayana Okazaki, Ryosuke Tsuge, Atsushi Manabe, Tomoki Taniguchi, Ryosuke Hiwa, Muneyuki Hatta, Mayu Shiomi, Ryu Watanabe and 7 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yuichi MasudaDepartment of Internal Medicine (Ⅳ), Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.
Shogo MatsudaDepartment of Internal Medicine (Ⅳ), Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan. shogo.matsuda@ompu.ac.jp.ORCID http://orcid.org/0000-0003-0023-3616
Ayana OkazakiDepartment of Internal Medicine (Ⅳ), Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.
Ryosuke TsugeDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Atsushi ManabeDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tomoki TaniguchiDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Ryosuke HiwaDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Muneyuki HattaDepartment of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Mayu ShiomiDepartment of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Ryu WatanabeDepartment of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Naoko SuwaDivision of Clinical Immunology and Rheumatology, Yodogawa Christian Hospital, Osaka, Japan.
Youhei FujikiDivision of Clinical Immunology and Rheumatology, Yodogawa Christian Hospital, Osaka, Japan.
Hirofumi MiyakeDepartment of General Internal Medicine, Tenri Hospital, Nara, Japan.
Wataru YamamotoDepartment of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan.
Motomu HashimotoDepartment of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Tohru TakeuchiDepartment of Internal Medicine (Ⅳ), Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.
Takuya KotaniDepartment of Internal Medicine (Ⅳ), Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPeripheral neuropathy (PN) is a severe manifestation of eosinophilic granulomatosis with polyangiitis (EGPA). However, the aetiology of PN in EGPA remains unclear. This study aimed to elucidate the clinical characteristics and prognosis of patients with EGPA with PN using a multicentre database in Japan.

methodsNewly diagnosed patients with EGPA between 2006 and 2024 were enrolled in this study. EGPA was diagnosed according to the ACR/EULAR 2022 classification criteria. Initial clinical characteristics were compared between patients with EGPA with and without PN based on BVAS ver. 3.0. The recurrence rate of PN in EGPA patients with neuropathy was also investigated, and risk factors for PN relapse were identified.

resultsOf the 159 patients enrolled in the REVEAL cohort, 107 newly diagnosed and treatment-naïve patients with EGPA were included. MPO-ANCA was positive in 45 patients (42.1%) and 93 patients (86.9%) had PN. The levels of WBC, eosinophil granulocyte, serum immunoglobulin (Ig)G, and serum IgG4 were significantly higher in patients with EGPA with PN than in those without PN. Among them, IgG4 was the most useful clinical indicator for detecting PN in patients with EGPA. Kaplan-Meier estimator showed that 5-year relapse rate of PN among patients with EGPA with PN was 18.6%. The administration rate of intravenous cyclophosphamide (IVCY) was significantly lower in patients with relapse of PN than in those without relapse of PN.

conclusionSerum IgG4 might be a useful clinical indicator for detecting PN in EGPA and IVCY administration might be effective in preventing PN relapse.

Indexed as

Granulomatosis with PolyangiitisPeripheral Nervous System DiseasesAdultAgedCohort StudiesFemaleHumansImmunoglobulin GJapanMaleMiddle AgedPrognosisRecurrenceImmunoglobulin GAntineutrophil cytoplasmic antibody-associated vasculitisEosinophilic granulomatosis with polyangiitisPeripheral neuropathy

Identifiers

PMID42832112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.